The FDA decision on Gilead Sciences Inc.’s (GILD) BIC/FTC/TAF, a triple-drug cocktail for the treatment of HIV-1 infection in adults will be known by February 12, 2018.
BIC/FTC/TAF is a fixed dose combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide.
A combination of Emtricitabine and Tenofovir Alafenamide as a single tablet under the name Descovy is already approved by the FDA.
GILD closed Thursday’s (Jan.25) trading at $81.19, down 0.14%.